Ascites: Pathogenesis and therapeutic principles

References

• Gines P, Cardenas A, Arroyo V, Rodes J. Management of cirrhosis and ascites. N Engl J Med 2004; 350: 1646–54
   PubMed Web of Science ®Google Scholar
• Henriksen, JH, Møller, S. Alterations of hepatic and splanchnic microvascular exchange in cirrhosis: local factors in the formation of ascites. In: P Gines, Arroyo, V, Rodes, J, Schrier, RW. Ascites and renal dysfunction in liver disease. Malden: Blackwell; 2005. pp 174–85.
   Google Scholar
• Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol 2003; 38(Suppl 1)S69–89
   PubMed Web of Science ®Google Scholar
• Moore KP, Wong F, Gines P, Bernardi M, Ochs A, Salerno F, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 2003; 38: 258–66
   PubMed Web of Science ®Google Scholar
• Fernandez-Esparrach G, Sanchez-Fueyo A, Gines P, Uriz J, Quinto L, Ventura PJ, et al. A prognostic model for predicting survival in cirrhosis with ascites. J Hepatol 2001; 34: 46–52
   PubMed Web of Science ®Google Scholar
• Guevara, M, Cardenas, A, Ginés, P, Prognosis of patients with cirrhosis and ascites. In: P Ginés, Arroyo, V, Rodes, J, Schrier, RW. Ascites and renal dysfunction in liver disease. Malden: Blackwell; 2005. pp 260–70
   Google Scholar
• Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology 2005; 41: 422–33
   PubMed Web of Science ®Google Scholar
• Arroyo V, Terra C, Gines P. Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome. J Hepatol 2007; 46: 935–46
   PubMed Web of Science ®Google Scholar
• Dagher L, Moore K. The hepatorenal syndrome. Gut 2001; 49: 729–37
   PubMed Web of Science ®Google Scholar
• Gentilini P, Vizzutti F, Gentilini A, Zipoli M, Foschi M, Romanelli RG. Update on ascites and hepatorenal syndrome. Dig Liver Dis 2002; 34: 592–605
   PubMedGoogle Scholar
• Bernardi, M, Caraceni, P.. Pathogenesis of ascites and hepatorenal syndrome: altered haemodynamics and neurohumoral systems. In: AL Gerbes, Beuers, U, Jungst, D, Pape, G, Sackmann, M, Sauerbruch, T. Hepatology 2000. Falk symposium 117. Dordrecht: Kluwer Academic Publishers; 2001. pp 185–203.
   Google Scholar
• Schrier RW. Decreased effective blood volume in edematous disorders: what does this mean?. J Am Soc Nephrol 2007; 18: 2028–31
   PubMed Web of Science ®Google Scholar
• Kravetz D, Bildozola M, Argonz J, Romero G, Korula J, Munoz A, et al. Patients with ascites have higher variceal pressure and wall tension than patients without ascites. Am J Gastroenterol 2000; 95: 1770–5
   PubMed Web of Science ®Google Scholar
• Plessier A, Valla DC. Budd-Chiari syndrome. Semin Liver Dis 2008; 28: 259–69
   PubMed Web of Science ®Google Scholar
• Garcia-Pagan JC, Hernandez-Guerra M, Bosch J. Extrahepatic portal vein thrombosis. Semin Liver Dis 2008; 28: 282–92
   PubMed Web of Science ®Google Scholar
• Bosch J, Abraldes JG, Groszmann R. Current management of portal hypertension. J Hepatol 2003; 38: S54–68
   PubMed Web of Science ®Google Scholar
• Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology 2006; 43: S121–31
   PubMed Web of Science ®Google Scholar
• Møller, S, Henriksen, JH, The systemic circulation in cirrhosis. In: P Gines, Arroyo, V, Rodes, J, Schrier, RW. Ascites and renal dysfunction in liver disease. Malden: Blackwell; 2005. pp 139–55.
   Google Scholar
• Henriksen JH, Siemssen O, Krintel JJ, Malchow-Moller A, Bendtsen F, Ring-Larsen H. Dynamics of albumin in plasma and ascitic fluid in patients with cirrhosis. J Hepatol 2001; 34: 53–60
   PubMed Web of Science ®Google Scholar
• Moore KP, Aithal GP. Guidelines on the management of ascites in cirrhosis. Gut 2006; 55(Suppl 6)vi1–vi12
   PubMedGoogle Scholar
• Casado M, Bosch J, Garcia-Pagan JC, Bru C, Banares R, Bandi JC, et al. Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology 1998; 114: 1296–303
   PubMed Web of Science ®Google Scholar
• Liu H, Schuelert N, McDougall JJ, Lee SS. Central neural activation of hyperdynamic circulation in portal hypertensive rats depends on vagal afferent nerves. Gut 2008; 57: 966–73
   PubMed Web of Science ®Google Scholar
• Wiest R. Splanchnic and systemic vasodilation: the experimental models. J Clin Gastroenterol 2007; 41: S272–87
   PubMed Web of Science ®Google Scholar
• Ruiz-Del-Arbol L, Monescillo A, Arocena C, Valer P, Gines P, Moreira V, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005; 42: 439–47
   PubMed Web of Science ®Google Scholar
• Ferguson JW, Dover A, Chia S, Cruden N, Hayes PC, Newby D. Inducible nitric oxide synthase activity contributes to the regulation of peripheral vascular tone in patients with cirrhosis and ascites. Gut 2005; 55: 542–6
   PubMed Web of Science ®Google Scholar
• Iwakiri Y, Groszmann RJ. Vascular endothelial dysfunction in cirrhosis. J Hepatol 2007; 46: 927–34
   PubMed Web of Science ®Google Scholar
• Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology 2002; 35: 478–91
   PubMed Web of Science ®Google Scholar
• Henriksen, JH, Møller, S. Hemodynamics, distribution of blood volume, and kinetics of vasoactive substances in cirrhosis. In: M Epstein. The kidney in liver disease. Philadelphia: Hanley and Belfus; 1996. pp 241–58.
   Google Scholar
• Farzaneh-Far R, Moore K. Nitric oxide and the liver. Liver 2001; 21: 161–74
   PubMedGoogle Scholar
• Helmy A, Newby DE, Jalan R, Johnston NR, Hayes PC, Webb DJ. Nitric oxide mediates the reduced vasoconstrictor response to angiotensin II in patients with preascitic cirrhosis. J Hepatol 2003; 38: 44–050
   PubMed Web of Science ®Google Scholar
• Møller S, Henriksen JH. Cardiovascular complications of cirrhosis. Gut 2008; 57: 268–78
   PubMed Web of Science ®Google Scholar
• Henriksen JH, Møller S, Schifter S, Abrahamsen J, Becker U. High arterial compliance in cirrhosis is related to elevated circulating calcitonin gene-related peptide (CGRP) and low adrenaline, but not to activated vasoconstrictor systems. Gut 2001; 49: 112–8
   PubMed Web of Science ®Google Scholar
• La Villa G, Salmeron JM, Arroyo V, Bosch J, Gines P, Garcia-Pagan JC, et al. Mineralocorticoid escape in patients with compensated cirrhosis and portal hypertension. Gastroenterology 1992; 102: 2114–9
   PubMed Web of Science ®Google Scholar
• Bernardi M, Li BS, Arienti V, de Collibus C, Scialpi C, Boriani L, et al. Systemic and regional hemodynamics in pre-ascitic cirrhosis: effects of posture. J Hepatol 2003; 39: 502–8
   PubMed Web of Science ®Google Scholar
• Wensing G, Lotterer E, Link I, Hahn EG, Fleig WE. Urinary sodium balance in patients with cirrhosis: relationship to quantitative parameters of liver function. Hepatology 1997; 26: 1149–55
   PubMed Web of Science ®Google Scholar
• Møller S, Henriksen JH. Pathogenesis and pathophysiology of hepatorenal syndrome: is there scope for prevention?. Aliment Pharmacol Ther 2004; 20(Suppl 3)31–41
   PubMed Web of Science ®Google Scholar
• Angeli P, Wong F, Watson H, Gines P. Hyponatremia in cirrhosis: results of a patient population survey. Hepatology 2006; 44: 1535–42
   PubMed Web of Science ®Google Scholar
• Bernardi M, Matco CD, Trevisani F, Collibus CD, Fornalé L, Baraldini M, et al. The hemodynamic status of preascitic cirrhosis: an evaluation under steady-state conditions and after postural change. Hepatology 1992; 16: 341–6
   PubMed Web of Science ®Google Scholar
• Sansoe G, Ferrari A, Baraldi E, Castellana CN, De Santis MC, Manenti F. Renal distal tubular handling of sodium in central fluid volume homoeostasis in preascitic cirrhosis. Gut 1999; 45: 750–5
   PubMed Web of Science ®Google Scholar
• Claria J, Rodes J. Renal sodium handling in preascitic cirrhosis. Gut 2001; 48: 740–1
   PubMed Web of Science ®Google Scholar
• Pozzi M, Grassi G, Redaelli E, Dell'Oro R, Ratti L, Redaelli A, et al. Patterns of regional sympathetic nerve traffic in preascitic and ascitic cirrhosis. Hepatology 2001; 34: 1113–8
   PubMed Web of Science ®Google Scholar
• Bernardi, M, Domenicali, M.. The renin-angiotensin-aldosterone system in cirrhosis. In: P Ginés, Arroyo, V, Rodes, J, Schrier, RW. Ascites and renal dysfunction in liver disease. Malden: Blackwell Publishing; 2005. pp 43–54.
   Google Scholar
• Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of the hepatorenal syndrome in cirrhosis. A consensus workshop of the International Ascites Club. Gut 2007; 56: 1310–8
   PubMed Web of Science ®Google Scholar
• Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis 2008; 28: 26–42
   PubMed Web of Science ®Google Scholar
• Salerno F, Restelli B, Incerti P, Annoni G, Capozza L, Badalamenti S, et al. Utility of ascitic fluid analysis in patients with malignancy-related ascites. Scand J Gastroenterol 1990; 25: 251–6
   PubMed Web of Science ®Google Scholar
• Ring-Larsen H, Henriksen JH, Wilken C, Clausen J, Pals H, Christensen NJ. Diuretic treatment in decompensated cirrhosis and congestive heart failure: effect of posture. Br Med J 1986; 292: 1351–3
   PubMed Web of Science ®Google Scholar
• Gerbes AL, Gulberg V, Gines P, Decaux G, Gross P, Gandjini H, et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: A randomized double-blind multicenter trial. Gastroenterology 2003; 124: 933–9
   PubMed Web of Science ®Google Scholar
• Gines P, Cardenas A. The management of ascites and hyponatremia in cirrhosis. Semin Liver Dis 2008; 28: 43–58
   PubMed Web of Science ®Google Scholar
• Fernandez-Esparrach G, Guevara M, Sort P, Pardo A, Jimenez W, Gines P, et al. Diuretic requirements after therapeutic paracentesis in non-azotemic patients with cirrhosis. A randomized double-blind trial of spironolactone versus placebo. J Hepatol 1997; 26: 614–20
   PubMed Web of Science ®Google Scholar
• Cabrera J, Falcon L, Gorriz E, Pardo MD, Granados R, Quinones A, et al. Abdominal decompression plays a major role in early postparacentesis haemodynamic changes in cirrhotic patients with tense ascites. Gut 2001; 48: 384–9
   PubMed Web of Science ®Google Scholar
• Pozzi M, Ratti L, Redaelli E, Guidi C, Mancia G. Cardiovascular abnormalities in special conditions of advanced cirrhosis. The circulatory adaptative changes to specific therapeutic procedures for the management of refractory ascites. Gastroenterol Hepatol 2006; 29: 263–72
   PubMedGoogle Scholar
• Gines P, Guevara M, De Las HD, Arroyo V. Review article: albumin for circulatory support in patients with cirrhosis. Aliment Pharmacol Ther 2002; 16(Suppl 5)24–31
   PubMed Web of Science ®Google Scholar
• Sola-Vera J, Minana J, Ricart E, Planella M, Gonzalez B, Torras X, et al. Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology 2003; 37: 1147–53
   PubMed Web of Science ®Google Scholar
• Salerno F, Badalamenti S, Lorenzano E, Moser P, Incerti P. Randomized comparative study of hemaccel vs. albumin infusion after total paracentesis in cirrhotic patients with refractory ascites. Hepatology 1991; 13: 707–13
   PubMed Web of Science ®Google Scholar
• Fassio E, Terg R, Landeira G, Abecasis R, Salemne M, Podesta A, et al. Paracentesis with Dextran 70 vs. paracentesis with albumin in cirrhosis with tense ascites. Results of a randomized study. J Hepatol 1992; 14: 310–6
   PubMed Web of Science ®Google Scholar
• Altman C, Bernard B, Roulot D, Vitte RL, Ink O. Randomized comparative multicenter study of hydroxyethyl starch versus albumin as a plasma expander in cirrhotic patients with tense ascites treated with paracentesis. Eur J Gastroenterol Hepatol 1998; 10: 5–10
   PubMed Web of Science ®Google Scholar
• Planas R, Gines P, Arroyo V, Llach J, Panes J, Vargas V, et al. Dextran-70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Gastroenterology 1990; 99: 1736–44
   PubMed Web of Science ®Google Scholar
• Gines A, Fernandez-Esparrach G, Monescillo A, Vila C, Domenech E, Abecasis R, et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996; 111: 1002–10
   PubMed Web of Science ®Google Scholar
• Moreau R, Valla DC, Durand-Zaleski I, Bronowicki JP, Durand F, Chaput JC, et al. Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trail. Liver Int 2006; 26: 46–54
   PubMed Web of Science ®Google Scholar
• Moreau R, Asselah T, Condat B, de Kerguenec C, Pessione F, Bernard B, et al. Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot study. Gut 2002; 50: 90–4
   PubMed Web of Science ®Google Scholar
• Singh V, Kumar B, Nain CK, Singh B, Sharma N, Bhalla A, et al. Noradrenaline and albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized pilot study. J Intern Med 2006; 260: 62–8
   PubMed Web of Science ®Google Scholar
• Krag A, Møller S, Henriksen JH, Holstein-Rathlou NH, Larsen FS, Bendtsen F. Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome. Hepatology 2007; 46: 1863–71
   PubMed Web of Science ®Google Scholar
• Singh V, Dheerendra PC, Singh B, Nain CK, Chawla D, Sharma N, et al. Midodrine versus albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotics: a randomized pilot study. Am J Gastroenterol 2008; 103: 1399–405
   PubMed Web of Science ®Google Scholar
• Appenrodt B, Wolf A, Grunhage F, Trebicka J, Schepke M, Rabe C, et al. Prevention of paracentesis-induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study. Liver Int 2008; 28: 1019–25
   PubMed Web of Science ®Google Scholar
• D'amico G, Luca A, Morabito A, Miraglia R, D'Amico M. Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis. Gastroenterology 2005; 129: 1282–93
   PubMed Web of Science ®Google Scholar
• Rössle M, Ochs A, Gulberg V, Siegerstetter V, Holl J, Deibert P, et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 2000; 342: 1701–7
   PubMed Web of Science ®Google Scholar
• Gines P, Uriz J, Calahorra B, Garcia-Tsao G, Kamath PS, del Arbol LR, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002; 123: 1839–47
   PubMed Web of Science ®Google Scholar
• Salerno F, Camma C, Enea M, Rossle M, Wong F. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology 2007; 133: 825–34
   PubMed Web of Science ®Google Scholar
• Saab, S, Nieto, JM, Lewis, SK, Runyon, BA. TIPS versus paracentesis for cirrhotic patients with refractory ascites. Cochrane Database Syst Rev 2006; CD004889.
   PubMed Web of Science ®Google Scholar
• Bureau C, Garcia-Pagan JC, Otal P, Pomier-Layrargues G, Chabbert V, Cortez C, et al. Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. Gastroenterology 2004; 126: 469–75
   PubMed Web of Science ®Google Scholar
• Arroyo V, Fernandez J, Gines P. Pathogenesis and treatment of hepatorenal syndrome. Semin Liver Dis 2008; 28: 81–95
   PubMed Web of Science ®Google Scholar
• Esteva-Font C, Baccaro ME, Fernandez-Llama P, Sans L, Guevara M, Ars E, et al. Aquaporin-1 and aquaporin-2 urinary excretion in cirrhosis: relationship with ascites and hepatorenal syndrome. Hepatology 2006; 44: 1555–63
   PubMed Web of Science ®Google Scholar
• Krag A, Bendtsen F, Pedersen EB, Holstein-Rathlou NH, Møller S. Effects of terlipressin on the aquaretic system: evidence of antidiuretic effects. Am J Physiol Renal Physiol 2008; 295: F1295–300
   PubMed Web of Science ®Google Scholar
• Gines P. Vaptans: A promising therapy in the management of advanced cirrhosis. J Hepatol 2007; 46: 1150–2
   PubMedGoogle Scholar
• Gerbes AL, Gulberg V. Progress in treatment of massive ascites and hepatorenal syndrome. World J Gastroenterol 2006; 12: 516–9
   PubMed Web of Science ®Google Scholar
• Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-Del-Arbol L, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341: 403–9
   PubMed Web of Science ®Google Scholar
• Fernandez J, Navasa M, Planas R, Montoliu S, Monfort D, Soriano G, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007; 133: 818–24
   PubMed Web of Science ®Google Scholar